Compare AstraZeneca plc (AZN) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Stanley Black & Decker, Inc. — how do they compare? AstraZeneca plc trades at $158.61 (market cap $248.14B), while Stanley Black & Decker, Inc. trades at $103.91 (market cap $15.71B). The key difference: AstraZeneca plc is far larger — about 15.8× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.23%). Which is the better fit depends on your goals.
| AZN | SWK | |
|---|---|---|
Market Cap | $248.14B | $15.71B |
Sector | Health | — |
52-Week High | $209.48 | $104.00 |
52-Week Low | $147.06 | $62.12 |
Enterprise Value | $275.41B | $19.87B |
Dividend Yield | 2.01% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Stanley Black & Decker (SWK) trades at $103.11, up 0.46% today, with a bullish technical signal from moving averages but overbought RSI readings near 80. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $1.57 exceeding expectations by 30%. Recent news highlights a $1 billion U.S. investment plan and strong institutional buying, while fundamentals show improving margins and debt reduction progress.
SWK presents a mixed outlook: positive earnings momentum and strategic initiatives support upside, but valuation appears stretched with a P/E of 25.4 above sector averages. Risks include competitive pressures and macroeconomic sensitivity. Analyst consensus is cautious with a hold-heavy rating and $93.67 price target below current levels, suggesting limited near-term upside despite operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
